BIOMEDICAL SEALANT MARKET ANALYSIS

Market News

Mergers and acquisitions by key players is also another factor expected to support the global biomedical sealant market growth. For instance, in January 2018, Baxter International Inc., a U.S.-based healthcare company, acquired two surgical products i.e. Recothrom and Preveleak of Mallinckrodt Pharmaceuticals—a producer of specialty pharmaceutical products. Recothrom is a thrombin based topical product, which is designed to assist hemostasis, this product is used when surgical methods to prevent flow of blood is ineffective in adults and pediatrics. Preveleak is a surgical sealant used to close suture holes to obtain hemostasis during surgical vascular reconstructions.

North America is expected to be dominant in the global biomedical sealant market over the forecast period. This is due to increasing product launches by key players in the region. For instance, in 2017, Starch Medical, a marketer and manufacturer of polysaccharide-based hemostatic products such as biomedical sealants, launched its new product Super Clot. Super Clot is a biomedical sealant used for effective and rapid hemostasis. Such new products in the market are expected to boost growth of the North America biomedical sealant market.